Nektar Therapeutics IncFind Ratings Reports
NEKTAR THERAPEUTICS's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. NEKTAR THERAPEUTICS is extremely liquid. Currently, the Quick Ratio is 5.60 which clearly shows the ability to cover any short-term cash needs. NKTR managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 1,270.74% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY16||Q4 FY15|
|Net Sales ($mil)||37.45||39.37|
|Net Income ($mil)||-42.2||-54.14|
|Balance Sheet||Q4 FY16||Q4 FY15|
|Cash & Equiv. ($mil)||389.1||308.94|
|Total Assets ($mil)||568.87||502.06|
|Total Debt ($mil)||354.55||366.98|
|Profitability||Q4 FY16||Q4 FY15|
|Gross Profit Margin||-75.55||-57.45|
|Return on Assets||-26.98||-16.16|
|Return on Equity||-174.21||-1262.66|
|Debt||Q4 FY16||Q4 FY15|
|Share Data||Q4 FY16||Q4 FY15|
|Shares outstanding (mil)||153.21||135.29|
|Div / share||0.0||0.0|
|Book value / share||0.58||0.05|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1247211.0||1909343.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 27.32 indicates a significant premium versus the S&P 500 average of 2.98 and a significant premium versus the industry average of 12.37. The current price-to-sales ratio is well above the S&P 500 average, but below the industry average. After reviewing these and other key valuation criteria, NEKTAR THERAPEUTICS proves to trade at a premium to investment alternatives within the industry.
|NKTR NM||Peers 46.51||NKTR NM||Peers 19.47|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
NKTR's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
NKTR's P/CF is negative making the measure meaningless.
|NKTR NM||Peers 14.92||NKTR NA||Peers 1.48|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
NKTR's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|NKTR 27.32||Peers 12.37||NKTR -80.32||Peers -2.04|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
NKTR is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, NKTR is expected to significantly trail its peers on the basis of its earnings growth rate.
|NKTR 14.55||Peers 14.81||NKTR -28.32||Peers 4.19|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
NKTR is trading at a valuation on par with its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
NKTR significantly trails its peers on the basis of sales growth